• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性进行性多发性硬化症的症状治疗与康复

Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis.

作者信息

Khan Fary, Amatya Bhasker, Turner-Stokes Lynne

机构信息

Department of Medicine, Dentistry and Health Sciences at The University of Melbourne, Royal Melbourne Hospital and Western Health, Rehabilitation Service-Royal Melbourne Hospital, Poplar Road, Parkville, Melbourne, VIC 3052, Australia.

出版信息

Neurol Res Int. 2011;2011:740505. doi: 10.1155/2011/740505. Epub 2011 Oct 17.

DOI:10.1155/2011/740505
PMID:22013521
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3196037/
Abstract

Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system and a major cause of chronic neurological disability in young adults. Primary progressive MS (PPMS) constitutes about 10% of cases, and is characterized by a steady decline in function with no acute attacks. The rate of deterioration from disease onset is more rapid than relapsing remitting and secondary progressive MS types. Multiple system involvement at onset and rapid early progression have a worse prognosis. PPMS can cause significant disability and impact on quality of life. Recent studies are biased in favour of relapsing remitting patients as treatment is now available for them and they are more likely to be seen at MS clinics. Since prognosis for PPMS is worse than other types of MS, the focus of rehabilitation is on managing disability and enhancing participation, and application of a "neuropalliative" approach as the disease progresses. This chapter presents the symptomatic treatment and rehabilitation for persons with MS, including PPMS. A multidisciplinary approach optimizes the intermediate and long-term medical, psychological and social outcomes in this population. Restoration and maintenance of functional independence and societal reintegration, and issues relating to quality of life are addressed in rehabilitation processes.

摘要

多发性硬化症(MS)是一种中枢神经系统的自身免疫性炎性脱髓鞘疾病,是年轻成年人慢性神经功能障碍的主要原因。原发性进展型多发性硬化症(PPMS)约占病例的10%,其特征是功能持续下降且无急性发作。从疾病发作开始的恶化速度比复发缓解型和继发进展型多发性硬化症更快。发病时多系统受累和早期快速进展预后较差。PPMS可导致严重残疾并影响生活质量。最近的研究偏向于复发缓解型患者,因为现在有针对他们的治疗方法,而且他们更有可能在多发性硬化症诊所就诊。由于PPMS的预后比其他类型的MS更差,康复的重点在于管理残疾和提高参与度,并在疾病进展过程中应用“神经姑息”方法。本章介绍了包括PPMS在内的多发性硬化症患者的对症治疗和康复。多学科方法可优化该人群的中期和长期医疗、心理和社会结局。康复过程中涉及功能独立性的恢复和维持、重新融入社会以及与生活质量相关的问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/386cf687753f/NRI2011-740505.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/66a758d0e3c0/NRI2011-740505.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/2b8a3f3f4726/NRI2011-740505.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/1bf714383c53/NRI2011-740505.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/5a3c9971e952/NRI2011-740505.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/5783c2c0c4a0/NRI2011-740505.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/f5fd03a9ef41/NRI2011-740505.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/a7bf4cbd2dae/NRI2011-740505.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/a768900736e8/NRI2011-740505.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/f8a5cbbadb64/NRI2011-740505.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/386cf687753f/NRI2011-740505.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/66a758d0e3c0/NRI2011-740505.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/2b8a3f3f4726/NRI2011-740505.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/1bf714383c53/NRI2011-740505.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/5a3c9971e952/NRI2011-740505.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/5783c2c0c4a0/NRI2011-740505.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/f5fd03a9ef41/NRI2011-740505.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/a7bf4cbd2dae/NRI2011-740505.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/a768900736e8/NRI2011-740505.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/f8a5cbbadb64/NRI2011-740505.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/264c/3196037/386cf687753f/NRI2011-740505.010.jpg

相似文献

1
Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis.原发性进行性多发性硬化症的症状治疗与康复
Neurol Res Int. 2011;2011:740505. doi: 10.1155/2011/740505. Epub 2011 Oct 17.
2
Azathioprine for people with multiple sclerosis.硫唑嘌呤用于多发性硬化症患者。
Cochrane Database Syst Rev. 2024 Dec 9;12(12):CD015005. doi: 10.1002/14651858.CD015005.pub2.
3
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.进行性阶段的发病是多发性硬化症中一个与年龄相关的临床里程碑。
Mult Scler. 2013 Feb;19(2):188-98. doi: 10.1177/1352458512451510. Epub 2012 Jun 26.
4
Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression.澳大利亚原发性进行性多发性硬化症的社会成本,以及一种假设的疾病修正治疗可能延迟疾病进展的经济影响。
J Med Econ. 2021 Jan-Dec;24(1):140-149. doi: 10.1080/13696998.2021.1872585.
5
Mitoxantrone: a review of its use in multiple sclerosis.米托蒽醌:其在多发性硬化症中的应用综述
CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010.
6
A comparison of serum inflammatory parameters in progressive forms of multiple sclerosis.多发性硬化进行性形式的血清炎症参数比较。
Mult Scler Relat Disord. 2023 Nov;79:105004. doi: 10.1016/j.msard.2023.105004. Epub 2023 Sep 11.
7
Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.原发性进行性和复发缓解型多发性硬化症之间的遗传差异:免疫相关基因变异性的影响。
Mult Scler Relat Disord. 2019 Apr;29:130-136. doi: 10.1016/j.msard.2019.01.033. Epub 2019 Jan 24.
8
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.血液神经丝轻链水平预测抗 CD20 治疗后复发缓解型和原发进展型多发性硬化的非复发进展:奥瑞珠单抗随机、双盲 3 期临床试验结果。
EBioMedicine. 2023 Jul;93:104662. doi: 10.1016/j.ebiom.2023.104662. Epub 2023 Jun 22.
9
Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.静脉注射免疫球蛋白治疗原发性和继发性慢性进行性多发性硬化症:一项随机安慰剂对照多中心研究。
Mult Scler. 2007 Nov;13(9):1107-17. doi: 10.1177/1352458507078400. Epub 2007 Jul 10.
10
Utility of an Untargeted Metabolomics Approach Using a 2D GC-GC-MS Platform to Distinguish Relapsing and Progressive Multiple Sclerosis.使用二维气相色谱-气相色谱-质谱平台的非靶向代谢组学方法区分复发型和进展型多发性硬化症的效用
Metabolites. 2024 Sep 11;14(9):493. doi: 10.3390/metabo14090493.

引用本文的文献

1
Cognitive-motor dual-task training improves dynamic stability during straight and curved gait in patients with multiple sclerosis: a randomized controlled trial.认知-运动双重任务训练改善多发性硬化症患者直线路径和曲线路径行走时的动态稳定性:一项随机对照试验。
Eur J Phys Rehabil Med. 2024 Feb;60(1):27-36. doi: 10.23736/S1973-9087.23.08156-X. Epub 2023 Nov 23.
2
Music-based therapy in rehabilitation of people with multiple sclerosis: a systematic review of clinical trials.基于音乐的疗法在多发性硬化症患者康复中的应用:临床试验的系统评价。
Arq Neuropsiquiatr. 2021 Jun;79(6):527-535. doi: 10.1590/0004-282X-ANP-2020-0374.
3

本文引用的文献

1
Cognitive-behavioral classifications of chronic pain in patients with multiple sclerosis.多发性硬化症患者慢性疼痛的认知行为分类
Int J Rehabil Res. 2011 Sep;34(3):235-42. doi: 10.1097/MRR.0b013e328347bdea.
2
Examining the benefits of combining two learning strategies on recall of functional information in persons with multiple sclerosis.探讨两种学习策略结合对多发性硬化症患者功能信息回忆的益处。
Mult Scler. 2011 Dec;17(12):1488-97. doi: 10.1177/1352458511406310. Epub 2011 May 17.
3
Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis.
Vigorous cool room treadmill training to improve walking ability in people with multiple sclerosis who use ambulatory assistive devices: a feasibility study.
使用助行器的多发性硬化症患者采用剧烈的凉爽室跑步机训练来改善步行能力:一项可行性研究。
BMC Neurol. 2020 Jan 22;20(1):33. doi: 10.1186/s12883-020-1611-0.
4
Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews.多发性硬化症患者的康复治疗:Cochrane系统评价综述
Cochrane Database Syst Rev. 2019 Jan 14;1(1):CD012732. doi: 10.1002/14651858.CD012732.pub2.
5
The "Surprise Question" in Neurorehabilitation-Prognosis Estimation by Neurologist and Palliative Care Physician; a Longitudinal, Prospective, Observational Study.神经科医生和姑息治疗医生在神经康复预后评估中的“意外问题”;一项纵向、前瞻性观察研究。
Front Neurol. 2018 Sep 24;9:792. doi: 10.3389/fneur.2018.00792. eCollection 2018.
6
Meeting the clinical needs of patients with progressive multiple sclerosis.满足进行性多发性硬化症患者的临床需求。
Clin Med (Lond). 2017 Jun;17(3):286. doi: 10.7861/clinmedicine.17-3-286.
7
Management of fatigue in persons with multiple sclerosis.多发性硬化症患者疲劳的管理。
Front Neurol. 2014 Sep 15;5:177. doi: 10.3389/fneur.2014.00177. eCollection 2014.
多奈哌齐治疗多发性硬化症记忆障碍的多中心随机临床试验。
Neurology. 2011 Apr 26;76(17):1500-7. doi: 10.1212/WNL.0b013e318218107a.
4
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.多发性硬化症的诊断标准:2010 年麦克唐纳标准修订版。
Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366.
5
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.一项扩展释放型口服地夫可特治疗多发性硬化症的 3 期临床试验。
Ann Neurol. 2010 Oct;68(4):494-502. doi: 10.1002/ana.22240.
6
A randomised controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis.一项随机对照试验:多发性硬化症患者膀胱康复的结果。
J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):1033-8. doi: 10.1136/jnnp.2010.206623. Epub 2010 Jun 11.
7
Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial.盐酸美金刚治疗多发性硬化认知障碍的随机安慰剂对照试验。
Mult Scler. 2010 Jun;16(6):715-23. doi: 10.1177/1352458510367662. Epub 2010 May 18.
8
Clinical practice improvement approach in multiple sclerosis rehabilitation: a pilot study.多发性硬化症康复中的临床实践改进方法:一项试点研究。
Int J Rehabil Res. 2010 Sep;33(3):238-47. doi: 10.1097/MRR.0b013e328338b05f.
9
A randomized trial of memantine as treatment for spasticity in multiple sclerosis.一项关于美金刚治疗多发性硬化痉挛的随机试验。
Mult Scler. 2010 Feb;16(2):248-51. doi: 10.1177/1352458509355462. Epub 2009 Dec 22.
10
Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort.多发性硬化症:澳大利亚社区队列中膀胱和肠道功能的流行情况及影响因素。
Disabil Rehabil. 2009;31(19):1567-76. doi: 10.1080/09638280802639566.